The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus
Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoiet...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Mohamed Salem [verfasserIn] Alaliaa Sallam [verfasserIn] Eman Amer [verfasserIn] Hala O. El-Mesallamy [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Archives of Pharmaceutical Sciences Ain Shams University - Ain Shams University, 2019, 3(2019), 2, Seite 277-284 |
|---|---|
| Übergeordnetes Werk: |
volume:3 ; year:2019 ; number:2 ; pages:277-284 |
| Links: |
Link aufrufen |
|---|
| Katalog-ID: |
DOAJ024304441 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ024304441 | ||
| 003 | DE-627 | ||
| 005 | 20230307073614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ024304441 | ||
| 035 | |a (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Mohamed Salem |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. | ||
| 650 | 4 | |a t2dm | |
| 650 | 4 | |a microalbuminuria | |
| 650 | 4 | |a diabetic nephropathy | |
| 650 | 4 | |a angiopoietin 2 | |
| 650 | 4 | |a endostatin | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Alaliaa Sallam |e verfasserin |4 aut | |
| 700 | 0 | |a Eman Amer |e verfasserin |4 aut | |
| 700 | 0 | |a Hala O. El-Mesallamy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Archives of Pharmaceutical Sciences Ain Shams University |d Ain Shams University, 2019 |g 3(2019), 2, Seite 277-284 |w (DE-627)1760642258 |x 23568399 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2019 |g number:2 |g pages:277-284 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.21608/aps.2019.16465.1009 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/09430f0862f64661b01286c77a4ce23d |z kostenfrei |
| 856 | 4 | 0 | |u https://aps.journals.ekb.eg/article_63658.html |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2356-8380 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2356-8399 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2019 |e 2 |h 277-284 | ||
| author_variant |
m s ms a s as e a ea h o e m hoem |
|---|---|
| matchkey_str |
article:23568399:2019----::hptnilsoedsaiadnipitnavlalboakrfrhpeitoodaein |
| hierarchy_sort_str |
2019 |
| callnumber-subject-code |
RM |
| publishDate |
2019 |
| allfields |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d DE-627 ger DE-627 rakwb eng RM1-950 Mohamed Salem verfasserin aut The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology Alaliaa Sallam verfasserin aut Eman Amer verfasserin aut Hala O. El-Mesallamy verfasserin aut In Archives of Pharmaceutical Sciences Ain Shams University Ain Shams University, 2019 3(2019), 2, Seite 277-284 (DE-627)1760642258 23568399 nnns volume:3 year:2019 number:2 pages:277-284 https://dx.doi.org/10.21608/aps.2019.16465.1009 kostenfrei https://doaj.org/article/09430f0862f64661b01286c77a4ce23d kostenfrei https://aps.journals.ekb.eg/article_63658.html kostenfrei https://doaj.org/toc/2356-8380 Journal toc kostenfrei https://doaj.org/toc/2356-8399 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 3 2019 2 277-284 |
| spelling |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d DE-627 ger DE-627 rakwb eng RM1-950 Mohamed Salem verfasserin aut The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology Alaliaa Sallam verfasserin aut Eman Amer verfasserin aut Hala O. El-Mesallamy verfasserin aut In Archives of Pharmaceutical Sciences Ain Shams University Ain Shams University, 2019 3(2019), 2, Seite 277-284 (DE-627)1760642258 23568399 nnns volume:3 year:2019 number:2 pages:277-284 https://dx.doi.org/10.21608/aps.2019.16465.1009 kostenfrei https://doaj.org/article/09430f0862f64661b01286c77a4ce23d kostenfrei https://aps.journals.ekb.eg/article_63658.html kostenfrei https://doaj.org/toc/2356-8380 Journal toc kostenfrei https://doaj.org/toc/2356-8399 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 3 2019 2 277-284 |
| allfields_unstemmed |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d DE-627 ger DE-627 rakwb eng RM1-950 Mohamed Salem verfasserin aut The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology Alaliaa Sallam verfasserin aut Eman Amer verfasserin aut Hala O. El-Mesallamy verfasserin aut In Archives of Pharmaceutical Sciences Ain Shams University Ain Shams University, 2019 3(2019), 2, Seite 277-284 (DE-627)1760642258 23568399 nnns volume:3 year:2019 number:2 pages:277-284 https://dx.doi.org/10.21608/aps.2019.16465.1009 kostenfrei https://doaj.org/article/09430f0862f64661b01286c77a4ce23d kostenfrei https://aps.journals.ekb.eg/article_63658.html kostenfrei https://doaj.org/toc/2356-8380 Journal toc kostenfrei https://doaj.org/toc/2356-8399 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 3 2019 2 277-284 |
| allfieldsGer |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d DE-627 ger DE-627 rakwb eng RM1-950 Mohamed Salem verfasserin aut The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology Alaliaa Sallam verfasserin aut Eman Amer verfasserin aut Hala O. El-Mesallamy verfasserin aut In Archives of Pharmaceutical Sciences Ain Shams University Ain Shams University, 2019 3(2019), 2, Seite 277-284 (DE-627)1760642258 23568399 nnns volume:3 year:2019 number:2 pages:277-284 https://dx.doi.org/10.21608/aps.2019.16465.1009 kostenfrei https://doaj.org/article/09430f0862f64661b01286c77a4ce23d kostenfrei https://aps.journals.ekb.eg/article_63658.html kostenfrei https://doaj.org/toc/2356-8380 Journal toc kostenfrei https://doaj.org/toc/2356-8399 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 3 2019 2 277-284 |
| allfieldsSound |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d DE-627 ger DE-627 rakwb eng RM1-950 Mohamed Salem verfasserin aut The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology Alaliaa Sallam verfasserin aut Eman Amer verfasserin aut Hala O. El-Mesallamy verfasserin aut In Archives of Pharmaceutical Sciences Ain Shams University Ain Shams University, 2019 3(2019), 2, Seite 277-284 (DE-627)1760642258 23568399 nnns volume:3 year:2019 number:2 pages:277-284 https://dx.doi.org/10.21608/aps.2019.16465.1009 kostenfrei https://doaj.org/article/09430f0862f64661b01286c77a4ce23d kostenfrei https://aps.journals.ekb.eg/article_63658.html kostenfrei https://doaj.org/toc/2356-8380 Journal toc kostenfrei https://doaj.org/toc/2356-8399 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 3 2019 2 277-284 |
| language |
English |
| source |
In Archives of Pharmaceutical Sciences Ain Shams University 3(2019), 2, Seite 277-284 volume:3 year:2019 number:2 pages:277-284 |
| sourceStr |
In Archives of Pharmaceutical Sciences Ain Shams University 3(2019), 2, Seite 277-284 volume:3 year:2019 number:2 pages:277-284 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin Therapeutics. Pharmacology |
| isfreeaccess_bool |
true |
| container_title |
Archives of Pharmaceutical Sciences Ain Shams University |
| authorswithroles_txt_mv |
Mohamed Salem @@aut@@ Alaliaa Sallam @@aut@@ Eman Amer @@aut@@ Hala O. El-Mesallamy @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
1760642258 |
| id |
DOAJ024304441 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024304441</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073614.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024304441</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ09430f0862f64661b01286c77a4ce23d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Salem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">t2dm</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">microalbuminuria</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diabetic nephropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiopoietin 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endostatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alaliaa Sallam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eman Amer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hala O. El-Mesallamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Pharmaceutical Sciences Ain Shams University</subfield><subfield code="d">Ain Shams University, 2019</subfield><subfield code="g">3(2019), 2, Seite 277-284</subfield><subfield code="w">(DE-627)1760642258</subfield><subfield code="x">23568399</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:277-284</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.21608/aps.2019.16465.1009</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/09430f0862f64661b01286c77a4ce23d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://aps.journals.ekb.eg/article_63658.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2356-8380</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2356-8399</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">277-284</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
Mohamed Salem |
| spellingShingle |
Mohamed Salem misc RM1-950 misc t2dm misc microalbuminuria misc diabetic nephropathy misc angiopoietin 2 misc endostatin misc Therapeutics. Pharmacology The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| authorStr |
Mohamed Salem |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760642258 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RM1-950 |
| illustrated |
Not Illustrated |
| issn |
23568399 |
| topic_title |
RM1-950 The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus t2dm microalbuminuria diabetic nephropathy angiopoietin 2 endostatin |
| topic |
misc RM1-950 misc t2dm misc microalbuminuria misc diabetic nephropathy misc angiopoietin 2 misc endostatin misc Therapeutics. Pharmacology |
| topic_unstemmed |
misc RM1-950 misc t2dm misc microalbuminuria misc diabetic nephropathy misc angiopoietin 2 misc endostatin misc Therapeutics. Pharmacology |
| topic_browse |
misc RM1-950 misc t2dm misc microalbuminuria misc diabetic nephropathy misc angiopoietin 2 misc endostatin misc Therapeutics. Pharmacology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Archives of Pharmaceutical Sciences Ain Shams University |
| hierarchy_parent_id |
1760642258 |
| hierarchy_top_title |
Archives of Pharmaceutical Sciences Ain Shams University |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760642258 |
| title |
The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| ctrlnum |
(DE-627)DOAJ024304441 (DE-599)DOAJ09430f0862f64661b01286c77a4ce23d |
| title_full |
The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| author_sort |
Mohamed Salem |
| journal |
Archives of Pharmaceutical Sciences Ain Shams University |
| journalStr |
Archives of Pharmaceutical Sciences Ain Shams University |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
277 |
| author_browse |
Mohamed Salem Alaliaa Sallam Eman Amer Hala O. El-Mesallamy |
| container_volume |
3 |
| class |
RM1-950 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mohamed Salem |
| author2-role |
verfasserin |
| title_sort |
potential use of endostatin and angiopoietin-2 as valuable biomarkers for the prediction of diabetic nephropathy in type 2 diabetes mellitus |
| callnumber |
RM1-950 |
| title_auth |
The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| abstract |
Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. |
| abstractGer |
Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. |
| abstract_unstemmed |
Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus |
| url |
https://dx.doi.org/10.21608/aps.2019.16465.1009 https://doaj.org/article/09430f0862f64661b01286c77a4ce23d https://aps.journals.ekb.eg/article_63658.html https://doaj.org/toc/2356-8380 https://doaj.org/toc/2356-8399 |
| remote_bool |
true |
| author2 |
Alaliaa Sallam Eman Amer Hala O. El-Mesallamy |
| author2Str |
Alaliaa Sallam Eman Amer Hala O. El-Mesallamy |
| ppnlink |
1760642258 |
| callnumber-subject |
RM - Therapeutics and Pharmacology |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RM1-950 |
| up_date |
2024-07-03T22:17:17.894Z |
| _version_ |
1803597945655787521 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024304441</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073614.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024304441</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ09430f0862f64661b01286c77a4ce23d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Mohamed Salem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The potential use of Endostatin and Angiopoietin-2 as valuable biomarkers for the prediction of Diabetic Nephropathy in Type 2 Diabetes Mellitus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetic Nephropathy (DN) is considered a serious capillary complication of diabetes mellitus (DM) which leads to end-stage renal disease. Endostatin (EST) is considered as collagen XVIII fragment formed during extracellular matrix remodeling (ECMR). EST acts as an anti-angiogenic factor. Angiopoietin-2 (Ang II) is a growth factor that increases in several conditions, such as hyperglycemia. The present study was to scrutinize the association of EST and Ang II serum levels with nephropathy in patients with type 2 diabetes mellitus (T2DM). A total of 30 healthy individuals (control) and 120 T2DM patients classified into 60 patients with microalbuminuria and 60 patients without microalbuminuria), aged 45-65 years were included. Fasting Plasma Glucose (FPG), HbA1C%, lipid profile, urinary albumin/creatinine ratio of 30-300 mg/g (UACR), serum urea and creatinine levels were assessed. Both EST and Ang II were measured using the ELISA technique. Ang II and EST levels were elevated in patients with T2DM groups compared with the healthy control group (P<0.001). EST and Ang II were significantly correlated to UACR (r= 0.753, P<0.001) (r= 0.685, P<0.001) and therefore indicate progress to DN. Circulating EST and Ang II were significantly associated with T2DM and predict progression of DN and therefore can be used as biomarkers for the prediction of DN in such a group of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">t2dm</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">microalbuminuria</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">diabetic nephropathy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">angiopoietin 2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">endostatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alaliaa Sallam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eman Amer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hala O. El-Mesallamy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Archives of Pharmaceutical Sciences Ain Shams University</subfield><subfield code="d">Ain Shams University, 2019</subfield><subfield code="g">3(2019), 2, Seite 277-284</subfield><subfield code="w">(DE-627)1760642258</subfield><subfield code="x">23568399</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:277-284</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.21608/aps.2019.16465.1009</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/09430f0862f64661b01286c77a4ce23d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://aps.journals.ekb.eg/article_63658.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2356-8380</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2356-8399</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2019</subfield><subfield code="e">2</subfield><subfield code="h">277-284</subfield></datafield></record></collection>
|
| score |
7.4004726 |